1228879-37-5

Basic information

• Product Name: benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride(dr>98/2)
• Synonyms: benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride(dr>98/2);raceMic 1-Benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride;3-Piperidinamine, N,4-dimethyl-1-(phenylmethyl)- (hydrochloride);N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine hydrochloride (1:2);benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride;benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride
• CAS NO: 1228879-37-5
• Molecular Formula: C14H24Cl2N2
• Molecular Weight: 291.25976
• EINECS: -0
• Mol File: 1228879-37-5.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride(dr>98/2)(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride(dr>98/2)(1228879-37-5)
• EPA Substance Registry System: benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride(dr>98/2)(1228879-37-5)

Safety Data

• Hazardous Substances Data: 1228879-37-5(Hazardous Substances Data)

Usage

General Description

Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride is a chemical compound that is used in the pharmaceutical industry as a key intermediate in the synthesis of various drugs. It is a white solid with high purity, with a minimum purity of 98% and a maximum impurity of 2%. The compound is a dihydrochloride salt form of benzyl-N,4-dimethylpiperidin-3-amine, which is a tertiary amine derivative. It is used as a building block in the production of pharmaceuticals, including antihistamines and antipsychotic drugs. benzyl-N,4-diMethylpiperidin-3-aMine dihydrochloride(dr>98/2) has important applications in the development of new medications and is used as a versatile intermediate in organic synthesis.

Upstream product

• 3430-27-1 3-amino-4-methylpyridine 
• 1354621-59-2 cis-N-benzyl-3-methoxycarbonylamino-4-methylpiperidine 
• 694495-63-1 O-methyl-N-(4-methylpyridin-3-yl)carbamate 
• 1204176-45-3 cis-3-methoxycarbonylamino-4-methylpiperidine 
• 142918-38-5 3-methoxy-4-methylpyridine 
• 3430-22-6 3-Bromo-4-methylpyridin 
• 32018-96-5 1-benzyl-4-methyl-piperidin-3-one 
• 14773-55-8 3-ethoxy-4-methylpyridine 
• 1354621-59-2 cis-(1-benzyl-4-methyl-piperidin-3-yl)-methyl-amine 
• 77862-24-9 4-Methyl-3-(methylamino)pyridine 

Downstream Products

• 540737-29-9 Tofacitinib citrate 
• 384336-73-6 (3R,4R)-methyl-(4-methyl-piperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine 
• 1259404-17-5 tasocitinib 
• 540737-29-9 tofacitinib citrate 
• 923036-25-3 (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 
• 477600-74-1 tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 
• 923036-30-0 N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-(7-p-toluenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1260590-51-9 ((3R,4R)-4-methylpiperidin-3-yl)-N-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine dihydrochloride 

Relevant articles and documents

Preparation method of tofacitinib intermediate cis-1-benzyl-N, 4-dimethylpiperidine-3-amine dihydrochloride

The invention discloses a preparation method of a tofacitinib intermediate cis-1benzyl-N, 4-dimethyl piperidine-3-amine dihydrochloride. The synthetic method comprises the following steps: taking 3-bromo-4-methylpyridine as an initial raw material, performing substitution reaction with amine to obtain a compound III, and performing acetyl or tert-butyloxycarbonyl protection and catalytic hydrogenation on the compound III to obtain a piperidine compound V. The compound V and benzaldehyde are subjected to reductive amination or react with benzyl halide to obtain a compound VI. A protecting groupis removed from the compound VI, and a hydrochloride compound I. 2HCl is formed at the same time. The synthesis method is simple to operate, high in total yield, high in product purity, stable in quality and suitable for industrial production.

Preparation methods of tofacitinib citrate intermediate and tofacitinib citrate

The invention discloses preparation methods of a tofacitinib citrate intermediate and tofacitinib citrate. The preparation method of the tofacitinib citrate intermediate comprises: preparing N-(1-benzyl-4-methyl-1,2,5,6-tetrahydropiperidine-3-yl)acetamide by using 3-amino-4-methyl-pyridine, acetyl chloride, benzyl chloride and sodium borohydride as raw materials; preparing 1-benzyl-N,4-dimethylpiperidine-3-amine by using the N-(1-benzyl-4-methyl-1,2,5,6-tetrahydropiperidine-3-yl)acetamide, hydrochloric acid, methylamine and sodium borohydride as raw materials; and carrying out resolution and dissociation on the 1-benzyl-N,4-dimethylpiperidine-3-amine, and carrying out salt forming with hydrochloric acid to obtain the product. The invention provides the new tofacitinib citrate intermediatepreparation method, wherein the use amount of the catalytic hydrogenation catalyst is reduced in the preparation process of tofacitinib citrate so as to reduce the cost, and the generation of N-alkylated impurities can be well controlled by adopting the isopropanol/water mixed solvent.

PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB

Object of the present invention is an improved process for the preparation of (3R,4R)-1-benzyl-4-methylpiperidin-3-amine by means of chiral Rhodium catalysts.